Retatrutide vs Mounjaro — the new era of obesity therapy

Modern metabolic medicine is going through a pivotal transformation. Medications that were initially created to treat type 2 diabetes have moved well beyond simple glycemic control and are now used as tools to regulate body weight at the level of neuroendocrine mechanisms.

Today, the spotlight is on Mounjaro (tirzepatide) and retatrutide — two molecules that are redefining the way obesity treatment is approached.

Mechanisms of action from appetite control to metabolic regulation

Tirzepatide became the first drug to integrate two key hormonal pathways into a single therapeutic strategy:

• GLP-1 — reduces appetite and slows gastric emptying
• GIP — enhances insulin secretion and improves metabolic sensitivity

Retatrutide advances this concept further. It is the first representative of a new class of triple agonists acting on:

• GLP-1
• GIP
• glucagon

The addition of glucagon fundamentally shifts the metabolic framework. While tirzepatide primarily works by decreasing energy intake, retatrutide exerts a broader effect by acting simultaneously on multiple metabolic processes. It:

• enhances lipolysis
• increases total energy expenditure
• activates thermogenesis

As a result, a dual mechanism is achieved — reduced caloric intake combined with increased energy output.

Efficacy approaching surgical-level outcomes

Clinical studies demonstrate that both medications lead to significant weight loss, although their magnitude of effect differs.

According to a phase II study published in The New England Journal of Medicine (2023), retatrutide achieved up to 24.2% weight reduction at moderate doses and up to 28.7% at higher doses.

For comparison, tirzepatide in the SURMOUNT-1 program demonstrated weight loss in the range of 20–22%.

In practical terms, these results approach those typically seen with bariatric surgery in certain patient populations.

The biochemical rationale behind superior performance

The key distinction of retatrutide lies in the combined activity of three hormonal pathways:

• GLP-1 reduces hunger through central nervous system mechanisms
• GIP improves metabolic flexibility and insulin sensitivity
• Glucagon stimulates energy expenditure

This makes retatrutide the first therapy capable of influencing both components of energy balance simultaneously:

• intake (energy consumption)
• output (energy expenditure)

Such an approach represents a shift in obesity treatment — from passive calorie restriction to active metabolic regulation.

The role of Mounjaro in current clinical practice

Despite the emergence of next-generation molecules, tirzepatide continues to hold a central position in obesity management.

Its key advantages include:

• a well-understood and predictable safety profile
• established and standardized dosing protocols

These characteristics make it the current benchmark in pharmacological obesity therapy.

Comparative table

Emerging scientific trends

One of the most actively discussed areas is the role of genetics in shaping treatment response. Variations in GLP-1 and GIP receptor activity may determine:

• the rate and magnitude of weight loss
• the severity of adverse effects
• the long-term sustainability of results

This is forming a new paradigm — personalized metabolic therapy.

In parallel, the range of potential indications is expanding. Beyond obesity, these therapies are being studied for their impact on:

• non-alcoholic fatty liver disease (NAFLD)
• cardiovascular risk
• systemic inflammation

Comparative table

Emerging scientific trends

One of the most actively discussed areas is the role of genetics in shaping treatment response. Variations in GLP-1 and GIP receptor activity may determine:

• the rate and magnitude of weight loss
• the severity of adverse effects
• the long-term sustainability of results

This is forming a new paradigm — personalized metabolic therapy.

In parallel, the range of potential indications is expanding. Beyond obesity, these therapies are being studied for their impact on:

• non-alcoholic fatty liver disease (NAFLD)
• cardiovascular risk
• systemic inflammation